PMID- 33099227
OWN - NLM
STAT- MEDLINE
DCOM- 20211012
LR  - 20211012
IS  - 1532-2238 (Electronic)
IS  - 1096-6374 (Linking)
VI  - 55
DP  - 2020 Dec
TI  - Effect of growth hormone treatment on circulating levels of NT-proBNP in patients 
      with ischemic heart failure.
PG  - 101359
LID - S1096-6374(20)30068-X [pii]
LID - 10.1016/j.ghir.2020.101359 [doi]
AB  - AIMS: Growth hormone (GH) therapy in heart failure (HF) is controversial. We 
      investigated the cardiovascular effects of GH in patients with chronic HF due to 
      ischemic heart disease. METHODS: In a double-blind, placebo-controlled trial, we 
      randomly assigned 37 patients (mean age 66 years; 95% male) with ischemic HF 
      (ejection fraction [EF] < 40%) to a 9-month treatment with either recombinant 
      human GH (1.4 mg every other day) or placebo, with subsequent 3-month 
      treatment-free follow-up. The primary outcome was change in left ventricular (LV) 
      end-systolic volume measured by cardiac magnetic resonance (CMR). Secondary 
      outcomes comprised changes in cardiac structure and EF. Prespecified tertiary 
      outcomes included changes in New York Heat Association (NYHA) functional class 
      and quality of life (QoL), as well as levels of insulin-like growth factor-1 
      (IGF-1) and N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS: No 
      changes in cardiac structure or systolic function were identified in either 
      treatment group; nor did GH treatment affect QoL or functional class. In the GH 
      group, circulating levels of IGF-1 doubled from baseline (+105%; p < 0.001) and 
      NT-proBNP levels halved (-48%; p < 0.001) during the treatment period, with 
      subsequently a partial return of both towards baseline levels. No changes in 
      IGF-1 or NT-proBNP were observed in the placebo group at any time during the 
      study. CONCLUSION: In patients with chronic ischemic HF, nine months of GH 
      treatment was associated with significant increases in levels of IGF-1 and 
      reductions in levels of NT-proBNP, but did not affect cardiac structure, systolic 
      function or functional capacity.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Karason, Kristjan
AU  - Karason K
AD  - Departments of Cardiology and Transplantation, Sahlgrenska University Hospital, 
      Gothenburg, Sweden; Institute of Medicine, Sahlgrenska Academy, University of 
      Gothenburg, Gothenburg, Sweden. Electronic address: kristjan.karason@gu.se.
FAU - Bobbio, Emanuele
AU  - Bobbio E
AD  - Departments of Cardiology and Transplantation, Sahlgrenska University Hospital, 
      Gothenburg, Sweden; Institute of Medicine, Sahlgrenska Academy, University of 
      Gothenburg, Gothenburg, Sweden.
FAU - Polte, Christian
AU  - Polte C
AD  - Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 
      Sweden; Departments of Clinical Physiology and Radiology, Sahlgrenska University 
      Hospital, Gothenburg, Sweden.
FAU - Bollano, Entela
AU  - Bollano E
AD  - Departments of Cardiology and Transplantation, Sahlgrenska University Hospital, 
      Gothenburg, Sweden; Institute of Medicine, Sahlgrenska Academy, University of 
      Gothenburg, Gothenburg, Sweden.
FAU - Peterson, Magnus
AU  - Peterson M
AD  - Department of Medicine, Lidkoping Hospital, Lidkoping, Sweden.
FAU - Cittadini, Antonio
AU  - Cittadini A
AD  - Department of Translational Medical Science, University of Naples Federico II, 
      Naples, Italy.
FAU - Caidahl, Kenneth
AU  - Caidahl K
AD  - Department of Molecular Medicine and Surgery, Karolinska Institute (KI), 
      Stockholm, Sweden.
FAU - Hjalmarson, Ake
AU  - Hjalmarson A
AD  - Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 
      Sweden.
FAU - Bengtsson, Bengt-Ake
AU  - Bengtsson BA
AD  - Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 
      Sweden.
FAU - Ekelund, Jan
AU  - Ekelund J
AD  - Centre of Registers Vastra Gotaland, Gothenburg, Sweden.
FAU - Swedberg, Karl
AU  - Swedberg K
AD  - National Heart and Lung Institute, Imperial College, London, UK.
FAU - Isgaard, Jorgen
AU  - Isgaard J
AD  - Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 
      Sweden; Department of Medicine, Sahlgrenska University Hospital, Gothenburg, 
      Sweden.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20201011
PL  - Scotland
TA  - Growth Horm IGF Res
JT  - Growth hormone & IGF research : official journal of the Growth Hormone Research 
      Society and the International IGF Research Society
JID - 9814320
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 12629-01-5 (Human Growth Hormone)
SB  - IM
MH  - Aged
MH  - Biomarkers/*blood
MH  - Case-Control Studies
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/blood/*drug therapy/pathology
MH  - Human Growth Hormone/*therapeutic use
MH  - Humans
MH  - Male
MH  - Myocardial Ischemia/blood/*drug therapy/pathology
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Prognosis
OTO - NOTNLM
OT  - Growth hormone
OT  - Heart failure
OT  - Insulin-like growth factor 1 (IGF-1)
OT  - Ischemic heart disease
OT  - N-terminal pro B-type natriuretic peptide (NT-proBNP)
EDAT- 2020/10/26 06:00
MHDA- 2021/10/13 06:00
CRDT- 2020/10/25 00:08
PHST- 2020/08/11 00:00 [received]
PHST- 2020/09/21 00:00 [revised]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2021/10/13 06:00 [medline]
PHST- 2020/10/25 00:08 [entrez]
AID - S1096-6374(20)30068-X [pii]
AID - 10.1016/j.ghir.2020.101359 [doi]
PST - ppublish
SO  - Growth Horm IGF Res. 2020 Dec;55:101359. doi: 10.1016/j.ghir.2020.101359. Epub 
      2020 Oct 11.